[1] 中国结直肠癌诊疗规范(2020年版)专家组.国家卫生健康委员会中国结直肠癌诊疗规范(2020年版)[J].中华胃肠外科杂志,2020,23(6):521-539. DOI:10.3760/cma.j.cn115610-20200504-00348. [2] GRAHAM J S, KAYE S B, BROWN R. The promises and pitfalls of epigenetic therapies in solid tumours[J]. European Journal of Cancer, 2009, 45(7):1129-1136. DOI:10.1016/j.ejca.2009.01.003. [3] JIANG Z F, LI W, HU X C, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer(ACE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20: 806-815. DOI:10.1016/S1470-2045(19)30164-0. [4] DICKINSON M, JOHNSTONE R W, PRINCE H M. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect[J]. Investigational New Drugs, 2010, 28(1):3-20. DOI:10.1007/s10637-010-9596-y. [5] ZHANG Q Y, WANG T, GENG C Z, et al. Exploratory clinical study of Chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer [J]. Chin J Cancer Res, 2018, 30: 605-612.DOI:10.21147/j.issn.1000-9604.2018.06.05. [6] ZHANG N N, LIANG C X, SONG W Y, et al. Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC[J]. J Cancer, 2019, 10: 1275-1287. DOI:10.7150/jca.28570. [7] YUAN X G,HUANG Y R,YU T, et al. Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspasedependent manner.[J].Oncol Lett, 2019, 18: 411-419. DOI:10.3892/ol.2019.10301. [8] DAWSON M, KOUZARIDES T. Cancer epigenetics: from mechanism to therapy[J]. Cell, 2012, 150(1):12-27. DOI:10.1016/j.cell.2012.06.013. [9] FRANKLIN, JAMES L. Redox regulation of the intrinsic pathway in neuronal apoptosis[J]. Antioxidants & Redox Signaling, 2011, 14(8):1437-1448. DOI:10.1089/ars.2010.3596. [10] KINNALLY K W, ANTONSSON B. A tale of two mitochondrial channels, MAC and PTP, in apoptosis[J]. Apoptosis, 2007, 12(5):857-868. DOI:10.1007/s10495-007-0722-z. [11] LIN L M,QUE Y M,LU P F, et al. Chidamide inhibits acute myeloid leukemia cell proliferation by incRNA VPS9D1-AS1 downregulation via MEK/ERK signaling pathway[J].Front Pharmacol, 2020, 11: 569651. DOI:10.3389/fphar.2020.569651. [12] CAO L X, ZHAO S R, YANG Q X, et al. Chidamide combined with doxorubicin induced p53-driven cell cycle arrest and cell apoptosis reverse multidrug resistance of breast cancer [J]. Front Oncol, 2021, 11: 614458. DOI:10.3389/fonc.2021.614458. [13] PENG J,LI S J,FU X, et al. Chidamide acts on the histone deacetylase-mediated miR-34a/Bcl-2 axis to regulate NB4 cell line proliferation and apoptosis[J].Kaohsiung J Med Sci, 2020, 36: 1004-1013. DOI:10.1002/kjm2.12283. [14] SHI P C, ZHANG L S, CHEN K, et al. Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage[J]. Pharmacogenomics, 2017, 18: 1259-1270. DOI:10.2217/pgs-2017-0061. [15] LIU L, QIU S, LIU Y, et al. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice[J]. Neoplasma, 2016, 63: 193-200. DOI:10.4149/203_150422N214. [16] ZHOU J N, ZHANG C J, SUI X X, et al. Histone deacetylase inhibitor Chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway[J]. Invest New Drugs, 2018, 36: 571-580. DOI:10.1007/s10637-017-0552-y. ( |